5/28/2014 9:20:44 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for COPAXONE® (glatiramer acetate injection) expiring September 9, 2025. In today's hearing, the European Patent Office specifically determined that claims 1-12 of the '528 patent are valid. Therefore infringing follow-on glatiramer products would not be able to launch prior to patent expiry.
Help employers find you! Check out all the jobs and post your resume.
comments powered by